STX140
STX140 is an orally active microtubule disruptor. STX140 induces apoptosis in the hormone-independent PC-3 prostate cell lines. STX140 has anti-angiogenic and anti-tumour activities.
For research use only. We do not sell to patients.
- CAS No.: 401600-86-0
- Formula: C19H28N2O7S2
- Molecular Weight:460.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | GI50 |
0.083 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human DU145 cell line
Growth inhibition of human DU145 cell line
|
[PMID: 17181151] |
| DU-145 | GI50 |
0.34 μM
Compound: 2
|
Antiproliferative activity against human DU145 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human DU145 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| DU-145 | GI50 |
0.34 μM
Compound: 3
|
Antiproliferative activity against human DU145 cells after 96 hrs by WST1 assay
Antiproliferative activity against human DU145 cells after 96 hrs by WST1 assay
|
[PMID: 17696419] |
| DU-145 | GI50 |
0.34 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human DU145 cells
Antiproliferative activity against human DU145 cells
|
[PMID: 18260615] |
| HCT-116 | GI50 |
0.045 μM
Compound: 2
|
Antiproliferative activity against human HCT116 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human HCT116 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| HCT-116 | GI50 |
0.045 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human HCT116 cell line
Growth inhibition of human HCT116 cell line
|
[PMID: 17181151] |
| HCT-116 | GI50 |
0.045 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human HCT116 cells
Antiproliferative activity against human HCT116 cells
|
[PMID: 18260615] |
| HOP-62 | GI50 |
0.051 μM
Compound: 2
|
Antiproliferative activity against human HOP62 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human HOP62 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| HOP-62 | GI50 |
0.051 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human HOP62 cell line
Growth inhibition of human HOP62 cell line
|
[PMID: 17181151] |
| HOP-62 | GI50 |
0.051 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human HOP62 cells
Antiproliferative activity against human HOP62 cells
|
[PMID: 18260615] |
| HUVEC | IC50 |
0.13 μM
Compound: 21, 2-MeOE2bisMATE
|
Antiangiogenic activity assessed as inhibition of cord formation in HUVEC
Antiangiogenic activity assessed as inhibition of cord formation in HUVEC
|
[PMID: 17181151] |
| HUVEC | IC50 |
0.4 μM
Compound: 21, 2-MeOE2bisMATE
|
Antiangiogenic activity in HUVEC by chemotaxis assay
Antiangiogenic activity in HUVEC by chemotaxis assay
|
[PMID: 17181151] |
| HUVEC | IC50 |
0.7 μM
Compound: 21, 2-MeOE2bisMATE
|
Antiangiogenic activity assessed as growth inhibition in HUVEC
Antiangiogenic activity assessed as growth inhibition in HUVEC
|
[PMID: 17181151] |
| HUVEC | IC50 |
44 nM
Compound: 3, 2-MeO2bisMATE
|
Antiangiogenic activity against HUVEC cells assessed as inhibition of proliferation
Antiangiogenic activity against HUVEC cells assessed as inhibition of proliferation
|
[PMID: 18260615] |
| MCF7 | GI50 |
0.25 μM
Compound: 21, 2-MeOE2bisMATE
|
Antiproliferative activity against human MCF7 cell line
Antiproliferative activity against human MCF7 cell line
|
[PMID: 17181151] |
| MCF7 | GI50 |
0.25 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against estrogen receptor positive human MCF7 cells
Antiproliferative activity against estrogen receptor positive human MCF7 cells
|
[PMID: 18260615] |
| MCF7 | IC50 |
0.25 μM
Compound: 15
|
Antiproliferative activity against estrogen receptor-positive human MCF7 cells
Antiproliferative activity against estrogen receptor-positive human MCF7 cells
|
[PMID: 31255926] |
| MDA-MB-231 | ED50 |
10 mg/kg
Compound: 43
|
Antitumor activity against human MDA-MB-231 cells xenografted in MF1 mouse administered daily
Antitumor activity against human MDA-MB-231 cells xenografted in MF1 mouse administered daily
|
[PMID: 25992880] |
| MDA-MB-231 | ED50 |
20 mg/kg
Compound: 43
|
Antitumor activity against human MDA-MB-231 cells xenografted in MF1 mouse administered thrice weekly
Antitumor activity against human MDA-MB-231 cells xenografted in MF1 mouse administered thrice weekly
|
[PMID: 25992880] |
| MDA-MB-231 | GI50 |
0.28 μM
Compound: 2
|
Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| MDA-MB-231 | GI50 |
0.28 μM
Compound: 3
|
Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST1 assay
Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST1 assay
|
[PMID: 17696419] |
| MDA-MB-231 | GI50 |
0.28 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells
Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells
|
[PMID: 18260615] |
| MDA-MB-231 | IC50 |
0.29 μM
Compound: 15
|
Antiproliferative activity against estrogen receptor-negative human MDA-MB-231 cells
Antiproliferative activity against estrogen receptor-negative human MDA-MB-231 cells
|
[PMID: 31255926] |
| MDA-MB-435 | GI50 |
<0.01 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human MDA-MB-435 cell line
Growth inhibition of human MDA-MB-435 cell line
|
[PMID: 17181151] |
| MDA-MB-435 | GI50 |
<0.01 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human MDA-MB-435 cells
Antiproliferative activity against human MDA-MB-435 cells
|
[PMID: 18260615] |
| OVCAR-3 | GI50 |
<0.01 μM
Compound: 2
|
Antiproliferative activity against human OVCAR-3 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human OVCAR-3 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| OVCAR-3 | GI50 |
<0.01 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human OVCAR-3 cell line
Growth inhibition of human OVCAR-3 cell line
|
[PMID: 17181151] |
| OVCAR-3 | GI50 |
<0.01 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human OVCAR-3 cells
Antiproliferative activity against human OVCAR-3 cells
|
[PMID: 18260615] |
| SF-539 | GI50 |
0.036 μM
Compound: 2
|
Antiproliferative activity against human SF539 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human SF539 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| SF-539 | GI50 |
0.036 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human SF539 cell line
Growth inhibition of human SF539 cell line
|
[PMID: 17181151] |
| SF-539 | GI50 |
0.036 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human SF539 cells at
Antiproliferative activity against human SF539 cells at
|
[PMID: 18260615] |
| SN12C | GI50 |
0.126 μM
Compound: 2
|
Antiproliferative activity against human SN12C cells after 96 hrs by WST-1 assay
Antiproliferative activity against human SN12C cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| SN12C | GI50 |
0.126 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human SN12-C cell line
Growth inhibition of human SN12-C cell line
|
[PMID: 17181151] |
| SN12C | GI50 |
0.126 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human SN12-C cells
Antiproliferative activity against human SN12-C cells
|
[PMID: 18260615] |
| UACC-62 | GI50 |
<0.01 μM
Compound: 2
|
Antiproliferative activity against human UACC62 cells after 96 hrs by WST-1 assay
Antiproliferative activity against human UACC62 cells after 96 hrs by WST-1 assay
|
[PMID: 20225862] |
| UACC-62 | GI50 |
<0.01 μM
Compound: 21, 2-MeOE2bisMATE
|
Growth inhibition of human UACC62 cell line
Growth inhibition of human UACC62 cell line
|
[PMID: 17181151] |
| UACC-62 | GI50 |
<0.01 μM
Compound: 3, 2-MeO2bisMATE
|
Antiproliferative activity against human UACC62 cells
Antiproliferative activity against human UACC62 cells
|
[PMID: 18260615] |
In Vitro
STX140 is a potent inhibitor of cell proliferation in a panel of prostate and breast cancer cell lines, with IC50 values of 270 nM, 290 nM, 260 nM, 250 nM, 280 nM, and 44 nM for PC-3, MDA-MB-231, LNCaP, MCF-7, A2780, and HUVEC, respectively[1].
STX140 (0.5 μM; 24 h) potently induces cell cycle arrest. STX140 induces apoptosis in the hormone-independent PC-3 prostate cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC-3 cells
-
Concentration:0.5 μM
-
Incubation Time:24 h
-
Result:Potently induced cell cycle arrest with 71% of PC-3 cells being in G2/M after 24 h and 6% in G1.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male MF-1 nu/nu mice injected with PC-3 cells[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; once daily; 60 days
-
Result:Led to tumour regression and complete responses.
Chemical Information
-
CAS No. 401600-86-0
-
Molecular Weight 460.56
-
Formula C19H28N2O7S2
-
SMILES
C[C@@]12[C@](CC[C@@H]2OS(N)(=O)=O)([H])[C@@]3([H])[C@@](CC1)([H])C4=CC(OC)=C(OS(N)(=O)=O)C=C4CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)